Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

The World’s Only Bioprosthetic Auto-regulated Artificial Heart: From Total Artificial Heart (TAH) to Physiologic Heart Replacement Therapy (PHRT)

Project description

The first advanced total artificial heart

End-stage biventricular heart failure represents the most severe manifestation of heart failure, necessitating heart transplants as the sole current therapeutic recourse. The EIC-funded Aeson® project will design an advanced total artificial heart (TAH), intended to supplant the ventricles in patients grappling with profound heart failure. This electro-hydraulically driven apparatus bears a resemblance to the human heart in shape. Diverging from existing artificial hearts, it emulates the actions of a natural heart through a distinctive triad of characteristics – pulsatility, autoregulation and haemocompatibility – thus offering mechanical circulatory support and reinstating typical blood circulation throughout the body. This innovation holds the potential to establish a novel therapeutic category termed physiologic heart replacement therapy, or PHRT.

Objective

At Carmat we have designed and developed Aeson®, the world’s most advanced total artificial heart (TAH), aiming to fulfill an unmet medical need by providing a credible therapeutic alternative to heart transplants for people suffering from end-stage biventricular heart failure. Aeson® is an active implantable medical device intended to replace the ventricles of the native heart in patients suffering from advanced heart failure. The device is electro-hydraulically driven with a shape close to that of a human heart. Once the Aeson® is powered, it mimics the action of a normal heart, providing mechanical circulatory support and restoring normal blood flow through the body.
Aeson® differs from other existing artificial hearts (or TAH – total artificial hearts) in its unique combination of three features: pulsatility, autoregulation and hemocompatibility. With Aeson®, Carmat is creating a new therapeutic class of “physiologic heart replacement therapy” (PHRT).

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2022-ACCELERATOR-01

See all projects funded under this call

Coordinator

CARMAT
Net EU contribution
€ 2 500 000,00
Address
36 AVENUE DE L'EUROPE
78140 Velizy-Villacoublay
France
SME
Yes
Region
Ile-de-France Ile-de-France Yvelines
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 11 560 168,75